RxDoctor Payments DataLook up a doctor →

Daniel Dees, MD

Neurology · Mobile, ALNPI 1700066677

Payments from drug & device makers

$894,258in general payments, 2019–2025

Across 1,556 payments — averaging $574.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$366K
  • AbbVie$151K
  • MDD US Operations, LLC$133K
  • Neurocrine Biosciences, Inc.$88K
  • Kyowa Kirin, Inc.$65K
  • Acadia Pharmaceuticals Inc$30K
  • plus $62K from 54 others

What the payments were for

  • Consulting fees$65,7468%
  • Speaking & faculty fees$600,78975%
  • Travel & lodging$93,60412%
  • Food & beverage$37,9295%
  • Education$4540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.382$366,248
AbbVie(2 entities)179$150,646
MDD US Operations, LLC235$133,042
Neurocrine Biosciences, Inc.158$87,518
Kyowa Kirin, Inc.72$64,733
Acadia Pharmaceuticals Inc81$30,242
Acorda Therapeutics, Inc57$28,444
Lundbeck LLC24$12,432
Sunovion Pharmaceuticals Inc.10$5,741
Amneal Pharmaceuticals LLC24$5,206
Abbott20$1,347
UCB, Inc.50$1,067
Medtronic(2 entities)21$813
Boston Scientific10$614
AstraZeneca(2 entities)25$601
Eisai Inc.21$484
Merz Pharmaceuticals, LLC10$434
Ipsen Biopharmaceuticals, Inc7$389
Amgen(2 entities)16$383
Biogen14$328
Novartis18$285
Merz North America, Inc.2$283
Genentech USA, Inc.11$245
Sanofi8$236
Lilly USA, LLC3$196
Jazz Pharmaceuticals Inc.6$161
EMD Serono, Inc.10$149
Argenx US, Inc.5$147
Tanabe Pharma America, Inc.7$128
SK Life Science, Inc.2$122
Revance Therapeutics, Inc.1$117
Pfizer6$116
Alnylam Pharmaceuticals Inc.4$116
Neurelis, Inc.5$111
Adamas Pharmaceuticals, Inc.5$97
Ceribell, Inc.1$92
Takeda Pharmaceuticals U.S.A., Inc.3$77
Octapharma USA, Inc.4$77
Greenwich Biosciences, Inc.4$74
Otsuka America Pharmaceutical, Inc.2$58
Johnson & Johnson(2 entities)3$49
Azurity Pharmaceuticals, Inc.2$46
Pyros Pharmaceuticals, Inc.2$45
Grifols USA, LLC2$44
Sumitomo Pharma America, Inc.2$42
Upsher-smith Laboratories LLC2$40
Intrabio Inc1$40
CSL Behring1$38
Zogenix Inc.2$34
Supernus Pharmaceuticals, Inc.2$32
Baxter Healthcare2$31
Portola Pharmaceuticals, LLC2$29
Immedica Pharma US, Inc.1$27
TG Therapeutics, Inc.1$24
Corium, LLC1$24
Mallinckrodt Hospital Products Inc.1$20
Akcea Therapeutics, Inc.1$19
Chiesi USA, Inc.1$16
ANI Pharmaceuticals, Inc.1$15
Bristol Myers Squibb1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894,258 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$90,721
Medicare patients
234
Services billed
4,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate75$749,029
Austedo XrDeutetrabenazine41$562,718
NuplazidPimavanserin Tartrate68$374,157
AustedoDeutetrabenazine17$250,668
RytaryCarbidopa/Levodopa25$58,499
NourianzIstradefylline20$54,187
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone78$41,198
Rasagiline Mesylate120$36,547
AptiomEslicarbazepine Acetate11$32,360
Carbidopa-LevodopaCarbidopa/Levodopa572$29,574
Entacapone61$17,438
Carbidopa15$9,823
Primidone95$4,453
Ropinirole ErRopinirole Hcl14$3,374
Clonazepam528$3,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$366,248$813,38658 claims
Neurocrine Biosciences, Inc.Ingrezza$87,518$749,02975 claims
Acadia Pharmaceuticals IncNuplazid$30,242$374,15768 claims
Amneal Pharmaceuticals LLCRytary$5,206$58,49925 claims
Kyowa Kirin, Inc.Nourianz$64,733$54,18720 claims
Sunovion Pharmaceuticals Inc.Aptiom$5,741$32,36011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 neurology providers in Alabama.

Other neurology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →